Edition:
United States

GlaxoSmithKline PLC (GSK.L)

GSK.L on London Stock Exchange

1,629.50GBp
23 May 2017
Change (% chg)

-- (--)
Prev Close
1,629.50
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
9,324,896
52-wk High
1,745.56
52-wk Low
1,363.00

Select another date:

Wed, May 17 2017

BRIEF-Kuehne und Nagel and GlaxoSmithKline expand partnership with new UK domestic distribution contract

* KUEHNE + NAGEL AND GLAXOSMITHKLINE EXPAND PARTNERSHIP WITH NEW UK DOMESTIC DISTRIBUTION CONTRACT Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Top-10 Glaxo investor Woodford sells out, criticises board

LONDON British fund manager Neil Woodford said on Friday he had sold out of pharma company GlaxoSmithKline after a "frustrating" stint as an investor spanning more than 15 years.

UPDATE 2-Top-10 Glaxo investor Woodford sells out, criticises board

* Buys into 'well-managed' Lloyds Banking Group (Adds Glaxo statement)

Top-10 Glaxo investor Woodford sells out, fires broadside at board

LONDON, May 12 High-profile British fund manager Neil Woodford said on Friday he had sold out of pharmaceutical company GlaxoSmithKline after holding shares in the company for more than 15 years.

GSK escapes Advair hit for now as second generic bid fails

LONDON GlaxoSmithKline is likely to escape generic competition to its blockbuster lung drug Advair in the United States this year, after a second application for a cut-price equivalent form of the medicine was turned down by U.S. regulators.

Hikma's generic Advair faces U.S. delay, 2017 approval unlikely

LONDON, May 11 Hikma Pharmaceuticals said on Thursday that U.S. regulators had decided not to approve its generic copy of GlaxoSmithKline's blockbuster lung drug Advair at this time, due to 'major' issues with its application.

BRIEF-GlaxoSmithKline announces positive results for asthma drug study

* Announced positive results from innovative Salford Lung Study (SLS) in asthma

BRIEF-Bluebird Bio enters into patent license agreement with Glaxosmithkline for commercialization of Gene Therapies

* Bluebird bio enters lentiviral vector patent license agreement with Glaxosmithkline for commercialization of gene therapies

BRIEF-Glaxo Smithkline Consumer Nig reports Q1 group loss before tax of 8.3 mln naira

* Q1 group loss before tax of 8.3 million naira versus profit of 167.5 million naira year ago

UPDATE 2-New GlaxoSmithKline CEO wants fewer, bigger new drug launches

* Q1 adjusted EPS 25.0 pence vs consensus 24.5p (Adds analyst comment, latest shares)

Select another date:

More From Around the Web